Reduced Size of Telangiectatic Capillaries After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents in Diabetic Macular Edema

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2023 Jan 26

PMID 36698851

Authors

Junichi Itou

Kei Furushima

Masatoshi Haruta

Nobuhiro Kato

Rikki Arai

Kenichiro Mori

Keijiro Ishikawa

Shigeo Yoshida

Affiliations

Soon will be listed here.

Abstract

Purpose: Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents reduces microaneurysms in patients with diabetic macular edema (DME). However, residual anti-VEGF-resistant telangiectatic capillaries (TelCaps) have been reported. In this study, we investigated changes in the size of TelCaps after intravitreal injection of anti-VEGF agents in DME.

Patients And Methods: Indocyanine green angiography (IA) and optical coherence tomography were performed before and 3 months after the intravitreal injection of anti-VEGF agents (pro re nata regimen after three monthly loading doses) in 12 eyes of 12 patients (7 males and 5 females, mean age 65.2 ± 8.8 years) with DME. The number and size of TelCaps within a 6-mm diameter macular region of the edema were measured using optical coherence tomography B-scan images overlaid on IA images.

Results: There were significant reductions in the number and size of TelCaps between the baseline and 3 months after anti-VEGF agent administration (P < 0.05 and P < 0.0001, respectively). The maximum corrected visual acuity (logMAR visual acuity) and the central macular thickness after anti-VEGF therapy were significantly improved (P < 0.01 and P < 0.02, respectively). The TelCaps remaining after loading three consecutive anti-VEGF agents had a significantly larger mean size at baseline than the TelCaps that resolved after the treatment (P < 0.03).

Conclusion: Our study demonstrated that intravitreal injection of anti-VEGF agents could reduce TelCap size in patients with DME. We propose that larger-sized TelCaps detected by IA might be useful predictors of refractory DME, which could thus be principal targets of laser photocoagulation.

Citing Articles

Characteristics of Microaneurysm Size in Residual Edema After Intravitreal Injection of Faricimab for Diabetic Macular Edema.

Yamada Y, Takamura Y, Morioka M, Oshima H, Gozawa M, Matsumura T J Clin Med. 2025; 13(24.

PMID: 39768761 PMC: 11677900. DOI: 10.3390/jcm13247839.

Current insights and challenges in the management of perifoveal vascular anomalous complex (PVAC): a systematic review of multimodal imaging features and treatment strategies.

Forte P, Feo A, Sarraf D, Romano M, Nicolo M Eye (Lond). 2024; 39(3):449-459.

PMID: 39702788 PMC: 11794436. DOI: 10.1038/s41433-024-03544-w.

Effectiveness of dexamethasone implants in treating diabetic macular edema with hard exudates: a clinical observation.

Zhao S, Liang X, Zhang J Int Ophthalmol. 2024; 44(1):377.

PMID: 39256259 PMC: 11387442. DOI: 10.1007/s10792-024-03278-4.

The Role of Laser Photocoagulation in Treating Diabetic Macular Edema in the Era of Intravitreal Drug Administration: A Descriptive Review.

Nozaki M, Ando R, Kimura T, Kato F, Yasukawa T Medicina (Kaunas). 2023; 59(7).

PMID: 37512130 PMC: 10385537. DOI: 10.3390/medicina59071319.

References

DE VENECIA G, Davis M, Engerman R . Clinicopathologic correlations in diabetic retinopathy. I. Histology and fluorescein angiography of microaneurysms. Arch Ophthalmol. 1976; 94(10):1766-73. DOI: 10.1001/archopht.1976.03910040540013. View

Nozaki M, Kato A, Yasukawa T, Suzuki K, Yoshida M, Ogura Y . Indocyanine green angiography-guided focal navigated laser photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2019; 63(3):243-254. DOI: 10.1007/s10384-019-00662-x. View

Allingham M, Mukherjee D, Lally E, Rabbani H, Mettu P, Cousins S . A Quantitative Approach to Predict Differential Effects of Anti-VEGF Treatment on Diffuse and Focal Leakage in Patients with Diabetic Macular Edema: A Pilot Study. Transl Vis Sci Technol. 2017; 6(2):7. PMC: 5374879. DOI: 10.1167/tvst.6.2.7. View

Castro Farias D, Matsui Serrano R, Bianchi Gancharov J, de Dios Cuadras U, Sahel J, Graue Wiechers F . Indocyanine green angiography for identifying telangiectatic capillaries in diabetic macular oedema. Br J Ophthalmol. 2019; 104(4):509-513. DOI: 10.1136/bjophthalmol-2019-314355. View

Elnahry A, Abdel-Kader A, Raafat K, Elrakhawy K . Evaluation of Changes in Macular Perfusion Detected by Optical Coherence Tomography Angiography following 3 Intravitreal Monthly Bevacizumab Injections for Diabetic Macular Edema in the IMPACT Study. J Ophthalmol. 2020; 2020:5814165. PMC: 7201518. DOI: 10.1155/2020/5814165. View

Bourhis A, Girmens J, Boni S, Pecha F, Favard C, Sahel J . Imaging of macroaneurysms occurring during retinal vein occlusion and diabetic retinopathy by indocyanine green angiography and high resolution optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2009; 248(2):161-6. DOI: 10.1007/s00417-009-1175-6. View

Dorrell M, Aguilar E, Scheppke L, Barnett F, Friedlander M . Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A. 2007; 104(3):967-72. PMC: 1764763. DOI: 10.1073/pnas.0607542104. View

Mori K, Yoshida S, Kobayashi Y, Ishikawa K, Nakao S, Hisatomi T . Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms. Graefes Arch Clin Exp Ophthalmol. 2020; 258(4):735-741. DOI: 10.1007/s00417-020-04608-9. View

Lee S, Chhablani J, Chan C, Wang H, Barteselli G, El-Emam S . Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema. Am J Ophthalmol. 2013; 155(5):905-12. PMC: 3627831. DOI: 10.1016/j.ajo.2012.12.005. View

10.

Choi M, Jee D, Kwon J . Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS One. 2019; 14(9):e0222364. PMC: 6742354. DOI: 10.1371/journal.pone.0222364. View

11.

Cho H, Rhee T, Kim H, Han J, Lee D, Cho S . Intravitreal bevacizumab for symptomatic retinal arterial macroaneurysm. Am J Ophthalmol. 2013; 155(5):898-904. DOI: 10.1016/j.ajo.2012.12.003. View

12.

Brown D, Schmidt-Erfurth U, Do D, Holz F, Boyer D, Midena E . Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015; 122(10):2044-52. DOI: 10.1016/j.ophtha.2015.06.017. View

13.

Leicht S, Kernt M, Neubauer A, Wolf A, Oliveira C, Ulbig M . Microaneurysm turnover in diabetic retinopathy assessed by automated RetmarkerDR image analysis--potential role as biomarker of response to ranibizumab treatment. Ophthalmologica. 2014; 231(4):198-203. DOI: 10.1159/000357505. View

14.

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

15.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R . The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615-25. DOI: 10.1016/j.ophtha.2011.01.031. View

16.

Sakono T, Terasaki H, Sonoda S, Funatsu R, Shiihara H, Uchino E . Comparison of multicolor scanning laser ophthalmoscopy and optical coherence tomography angiography for detection of microaneurysms in diabetic retinopathy. Sci Rep. 2021; 11(1):17017. PMC: 8382757. DOI: 10.1038/s41598-021-96371-y. View

17.

Murakami T, Nishijima K, Sakamoto A, Ota M, Horii T, Yoshimura N . Foveal cystoid spaces are associated with enlarged foveal avascular zone and microaneurysms in diabetic macular edema. Ophthalmology. 2010; 118(2):359-67. DOI: 10.1016/j.ophtha.2010.03.035. View

18.

Chaperon M, Kodjikian L, Agard E, Mathis T, Billant J, El-Chehab H . Screening of telangiectatic capillaries in chronic macular edema based on multimodal imaging: a study of 101 eyes. LyoMAC1 study. Graefes Arch Clin Exp Ophthalmol. 2022; 260(8):2501-2508. DOI: 10.1007/s00417-022-05592-y. View

19.

Das A, McGuire P, Rangasamy S . Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015; 122(7):1375-94. DOI: 10.1016/j.ophtha.2015.03.024. View

20.

Ishibashi T, Li X, Koh A, Lai T, Lee F, Lee W . The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology. 2015; 122(7):1402-15. DOI: 10.1016/j.ophtha.2015.02.006. View